Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.55 |
| ▸ | DRD4 | P21917 | 4/20 | 0.54 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.53 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587801 | 0.92 | SIGMAR1 (0.61) | SIGMAR1DRD4TEAD1CXCR3L3MBTL1 | |
| SCHEMBL3590338 | 0.85 | SIGMAR1 (0.73) | SIGMAR1DRD4TEAD1LMNA | |
| SCHEMBL3586725 | 0.84 | DRD2 (0.58) | SIGMAR1DRD4CXCR3C5AR1HRH3 | |
| SCHEMBL19692557 | 0.82 | HRH3 (0.64) | SIGMAR1HRH3 | |
| SCHEMBL3596491 | 0.82 | DRD2 (0.50) | SIGMAR1TEAD1HRH3 | |
| SCHEMBL10340656 | 0.80 | IGF1R (0.49) | SIGMAR1DRD4TEAD1CXCR3L3MBTL1 | |
| SCHEMBL4305546 | 0.80 | L3MBTL1 (0.64) | SIGMAR1DRD4CXCR3L3MBTL1HRH3 | |
| SCHEMBL22716940 | 0.80 | DRD2 (0.66) | SIGMAR1DRD4TEAD1 | |
| SCHEMBL27430491 | 0.79 | SIGMAR1 (0.79) | SIGMAR1DRD4CXCR3 | |
| SCHEMBL3598496 | 0.79 | HRH3 (0.49) | SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | claimed |
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | disclosed |
| EP-1720550-A1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | Sanofi-Aventis (FR) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005089759-A1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | SIGMAR1 2487/4885DRD4 2463/4885TEAD1 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.